Company intelligence / Profile preview

Type6 Therapeutics

South San Francisco, California, United States

Ownership: Private
Development stage: Preclinical

Overview

Type6 Therapeutics develops first-in-class small molecule therapeutics that target disease-driving kinases at their most vulnerable "OFF-state," aiming to overcome resistance mechanisms in aggressive cancers. Their lead program focuses on a novel CDK2 inhibitor with preclinical proof-of-concept. The company’s approach offers unmatched selectivity and durability compared to traditional ON-state kinase inhibitors. Additional programs are being developed against other high-value kinase targets using the same proprietary platform.

Therapeutic areas: Oncology
Modalities: Small molecule kinase inhibitorsAntibody-drug conjugates (ADCs)Bifunctional/bivalent small molecules
Industry: Biotech

Drug pipeline

1 asset

Type6 CDK2 inhibitor

Preclinical

Beyond the preview

Go deeper on Type6 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Type6 Therapeutics.

Explore the full profile